Pharmacology

Drugs Update: New FDA approved Drugs

FDA pushed out 4 big approvals.

  • Cholesterol-reducing PCSK9 inhibitors: Sanofi and Regeneron’s Praluent
  • Technivie (ombitasvir, paritaprevir and ritonavir) for Chronic Hepatitis C Genotype 4 Infections
  • Odomzo (sonidegib), a hedgehog pathway inhibitor for basal cell carcinoma
  • Kyprolis (carfilzomib) for Combination Treatment of Patients with Relapsed Multiple Myeloma
  • Praluent (alirocumab) to Treat Certain Patients with High Cholesterol
  • Daklinza (daclatasvir) for Chronic Hepatitis C Genotype 3 Infections

REFERENCE: 

CIMS

Leave a Reply